Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained a complete molecular response for at least 2 years: the multicentre Stop Imatinib (STIM) trial
Nom du journal : Lancet Oncol
Année : 2010
Volume : 11
Page de départ : 1029
Page de fin : 1035